GlassScriptPhysician profile
Imad Karam
NPI 1770193054
$5,519.89
in general payments reported to CMS, 2019-2025
33 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $249 · 2022: $173 · 2023: $2,031 · 2024: $1,497 · 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,189 · Education: $910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,189.02 |
| Education | $909.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $577.01 | 2023-2025 | Darzalex, Tecvayli, Carvykti |
| Seagen INC. | $501.75 | 2023 | Adcetris, Tukysa |
| Astrazeneca Pharmaceuticals LP | $402.21 | 2023-2024 | Tagrisso, Calquence |
| E.R. Squibb & Sons, L.L.C. | $372.90 | 2024-2025 | Opdivo |
| Daiichi Sankyo INC. | $331.25 | 2024-2025 | Enhertu |
| Genzyme Corporation | $291.46 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $289.92 | 2021-2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $284.84 | 2023-2025 | Libtayo |
| Pfizer INC. | $278.13 | 2022-2025 | |
| Lilly USA, LLC | $262.97 | 2023-2024 | Verzenio, Retevmo, Jaypirca |
| Amgen INC. | $249.97 | 2023-2025 | Kyprolis, Blincyto |
| Gilead Sciences, INC. | $244.55 | 2023-2025 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $239.52 | 2024-2025 | Ultomiris |
| Abbvie INC. | $158.96 | 2023-2025 | |
| Eisai INC. | $149.88 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $131.06 | 2023 | Cabometyx |
| Incyte Corporation | $126.09 | 2023-2025 | Jakafi |
| Taiho Oncology, INC. | $103.67 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.60 | 2024 | |
| Puma Biotechnology, INC. | $59.26 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $53.85 | 2024-2025 | Orgovyx |
| Novartis Pharmaceuticals Corporation | $43.04 | 2022-2025 | |
| Celgene Corporation | $41.44 | 2025 | Reblozyl |
| Jazz Pharmaceuticals INC. | $36.32 | 2025 | |
| Karyopharm Therapeutics INC. | $33.65 | 2023 | Xpovio |
| Genentech USA, INC. | $30.87 | 2023-2024 | Phesgo, Itovebi |
| Syndax Pharmaceuticals, INC. | $27.45 | 2025 | Revuforj |
| Blueprint Medicines Corporation | $26.60 | 2024 | Ayvakit |
| Servier Pharmaceuticals LLC | $24.25 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.38 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $17.53 | 2023 | Jynarque |
| Glaxosmithkline, LLC. | $16.64 | 2023 | Shingrix |
| Array Biopharma INC | $15.87 | 2025 | Mektovi, Tukysa, Braftovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imad Karam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.